ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
24
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
4,637
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Seasonal influenza vaccination in patients with chronic lymphocytic leukemiatreated with Ibrutinib
Author(s):
C SUN
,
J Gao
,
L Couzens
,
X Tian
,
M.Z. Farooqui
,
M.C. Eicheberger
Publication date:
2016
Journal:
JAMA Oncol
Read this article at
ScienceOpen
Publisher
PubMed
Further versions
open (via free pdf)
oa repository (via OAI-PMH doi match)
oa repository (via pmcid lookup)
Powered by
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Jiangsu Journal of Preventive Medicine
Author and article information
Journal
DOI::
10.1001/jamaoncol.2016.2070
PubMed ID::
27533065
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
4,637
CB1763, a highly selective, novel non-covalent BTK inhibitor, targeting ibrutinib-resistant BTK C481S mutant
Authors:
T ASAMI
,
W Kawahata
,
S. Kashimoto
…
Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial
Authors:
Peter Hillmen
,
Alexandra Pitchford
,
Adrian Bloor
…
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment
Authors:
D. Jones
,
JA Woyach
,
W Zhao
See all similar
Cited by
1
Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2
Authors:
Bruno Fattizzo
,
Nicolò Rampi
,
Wilma Barcellini
See all cited by